Big Pharma
-
Intellectual Property
Why Assigning Patents To Native American Tribes To Avoid Inter Partes Review Is Bad Medicine
Here are three big reasons why, according to IP columnist Tom Kulik. -
Intellectual Property
A New Patent Loophole? Paying Off A Native American Tribe To Exploit Its Sovereign Immunity
If this tactic is allowed, it will be a big win for Big Pharma -- and a big loss for patients and consumers. - Sponsored
Early Adopters Of Legal AI Gaining Competitive Edge In Marketplace
How to best leverage generative AI as an early adopter with ethical use. -
Health Care / Medicine
Pharma Companies Routinely Bend Rules Under Orphan Drug Act
A Kaiser Health News investigation shows that the system intended to help desperate patients is being manipulated by drugmakers to maximize profits,
-
Biglaw
Biglaw Firm Gets Benchslapped Over Conflicts
Which Biglaw firm got blasted for ignoring its ethical obligations in a hostile takeover bid? -
11th Circuit, Antitrust, Drugs, Intellectual Property, Patents, SCOTUS, Supreme Court
When Buying Off A Litigant Is Also Buying Off A Competitor
According to the Supreme Court, sometimes settling a lawsuit can create an antitrust problem. How? -
Accounting / Accountants, Drugs, In-House Counsel, Litigators, Music, Plaintiffs Firms
Inside Straight: Learning Who To Hate
Cops learn to hate people. Basically everyone they encounter is a criminal, so cops soon come to believe that everyone is a criminal. Litigators — or perhaps litigators who are repeat players in a particular field — learn to hate people. Personal injury insurance defense counsel come to believe that all plaintiffs are lying fakers. […] -
Amy Schulman, Biglaw, Drugs, In-House Counsel, Litigators, Williams & Connolly
Inside Straight: Pfortune On Pfizer
Columnist Mark Herrmann thinks that you should read the long piece in Fortune magazine about the rise and fall of Jeff Kindler as the CEO of Pfizer because it gives some insight on life as an in-house attorney.... -
In-House Counsel, Merck, Money, Skaddenfreude, Vioxx
Skaddenfreude: In-House Salaries, Please
This item, from yesterday’s WSJ Law Blog, caught our eye: As the 11th Vioxx trial got underway yesterday in federal court in New Orleans, Merck disclosed in an SEC filing that it’s giving its general counsel Kenneth Frazier a raise and a promotion, effective Nov. 1. The GC who will forever be associated with the […]
Sponsored
Sponsored
Legal AI: 3 Steps Law Firms Should Take Now
If 2023 introduced legal professionals to generative AI, then 2024 will be when law firms start adapting to utilize it. Things are moving fast, so…
Sponsored
Early Adopters Of Legal AI Gaining Competitive Edge In Marketplace
How to best leverage generative AI as an early adopter with ethical use.
Sponsored
Profit Powerhouse: Elevating Law Firm Financial Performance
In this CLE-eligible webinar on April 10th, we’ll explore the most common accounting pitfalls and how to avoid them for your firm.